April 2017

Event Participation 2017

Banook Group will attend the following exhibitions. Let’s meet there!
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in…
Read the full post
May 2016

Webinar : ECG Assessment in Early Phase 1 Studies: How to get it right for possible TQT waiver?

Reserve your webinar seat now (limited number of places)   Click here :…
Read the full post
March 2015

Banook Group - New branding announcement

Cardiabase/Banook Central Imaging becomes Banook Group - New branding announcement.
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation…
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation of tumor size and determination of response using the RECIST criteria. In this talk, we will explore the use of more advanced imaging techniques as tools to advance precision medicine.

 

Duration:  1 hour.

 

Presenters: 

Xavier Tizon, PhD., Head of the imaging lab, Oncodesign 

Gérard Nitenberg, Ph.D., CEO Europe & Scientific Advisor, Banook Central Imaging.

 

Agenda:
In a first part, Gérard Nitenberg, CEO Europe and Scientific Advisor at Banook Central Imaging will describe a methodology based on the original approach of the DITEP* at the “Institut Gustave Roussy”. The evaluation of treatment response by RECIST does not take into account kinetics of tumor growth at the pre-treatment phase and along the entire treatment sequence, and may provide misleading information on drug activity. Adding Tumor Growth Rate (TGR) assessment in Phase I and Phase III clinical trials is simple and provides clinically relevant information: (i) It allows for an early and precise assessment of the tumor growth, (ii) It reveals drug-specific profiles, suggesting its potential use for the early assessment of drug activity, (iii) TGR is independently associated with prognosis both in ear! ly clinical trials and in phase III setting.

 

In a second part, Xavier Tizon, head of the imaging lab at Oncodesign, will present two functional imaging modalities based on MRI: diffusion-weighted imaging (Dw-MRI) and Dynamic Contrast-Enhanced MRI (DCE-MRI). Dw-MRI gives measures of tissue architecture at the cellular level, whereas DCE-MRI provides information on the vascular status of tumors. Both methods have been standardized and used extensively as early PD biomarkers of the efficacy of anticancer therapies. He will describe, through preclinical and clinical case studies, how these two techniques can be used to evaluate the activity of novel drug candidates.

 

*DITEP : Département des Innovations Thérapeutiques Précoces

 

To know more:

https://www.youtube.com/watch?v=pC58Vkt8coY